September 1, 2020, via webinar With well over 22 million cases and 700,000 deaths globally, the world desperately awaits a vaccine that can finally put an end to the COVID-19 pandemic. One of the most promising vaccines, developed by researchers at Oxford University and funded by AstraZeneca, moved into Phase 3 clinical trials in August at 100 sites nationwide, including in Kansas City at the University of Kansas Medical Center and Children’s Mercy Hospital. The speaker: Dr. Barbara Pahud is an infectious disease specialist and Associate Professor of Pediatrics at University of Missouri- Kansas City and Children’s Mercy Hospital, where she also serves as Associate Director of the NIH’s Vaccine Treatment and Evaluation Unit. Dr. Pahud is co-primary investigator alongside Dr. Mario Castro of the Phase 3 clinical trials of the COVID-19 vaccine AZD1222. She received her medical degree from La Salle University in Mexico City, Mexico and holds a Master of Public Health degree from Columbia University in New York. She completed her residency in pediatrics at Maimonides Medical Center in Brooklyn, New York and has completed fellowships at University of California, San Francisco and the Centers for Disease Control in collaboration with Stanford University Medical Center.

Be the first to comment